Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from nevirapine-based HAART to Eviplera in virologically suppressed HIV-1 patients
NL-OMON26054Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1, sponsored by Erasmus MC. Started Nov 2013; status: recruiting.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON26054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26054.